Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor – Yahoo Finance

Seventh Approval Worldwide for QINLOCK and First European Approval –
WALTHAM, Mass., October 12, 2021–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for QINLOCK (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib1.
"We are committed to delivering this much-needed medicine to patients globally, and are thrilled that we have received approval in Switzerland, which is our seventh approval worldwide and the first in Europe," said Steve Hoerter, President and Chief Executive Officer of Deciphera. "Following a positive opinion earlier this month from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), we look forward to a potential approval from the European Commission (EC) for QINLOCK in the fourth quarter of this year, and to ensuring that GIST patients across the EU have access to this treatment option designed specifically for their disease."
The application for QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study of QINLOCK in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of QINLOCK. In INVICTUS, QINLOCK demonstrated a median progression-free survival of 6.3 months compared to 1.0 month in the placebo arm and significantly reduced the risk of disease progression or death by 85% (hazard ratio of 0.15, p<0.0001). Secondary endpoints as determined by independent radiologic review using modified RECIST include Objective Response Rate (ORR) and Overall Survival (OS). QINLOCK demonstrated an ORR of 9.4% compared with 0% for placebo (p =0.0504)2. In addition, QINLOCK demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64% (hazard ratio of 0.36) 2.
The most frequently observed adverse drug reactions (≥20%) in patients treated with QINLOCK were fatigue, alopecia, nausea, myalgia, constipation, diarrhea, palmar-plantar erythrodysesthesia syndrome (PPES), weight decreased, vomiting, lipase increased, muscle spasms, arthralgia, headache and dyspnoea1,2.
In the INVICTUS study, adverse reactions resulting in permanent discontinuation occurred in 8% of patients, dosage interruptions due to an adverse reaction occurred in 24% of patients and dose reductions due to an adverse reaction occurred in 7% of patients who received QINLOCK 1,2.
About QINLOCK (ripretinib)
QINLOCK is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop. QINLOCK inhibits primary and secondary KIT mutations in exons 9, 11, 13, 14, 17, and 18 involved in GIST, as well as the primary exon 17 D816V mutation. QINLOCK also inhibits primary PDGFRA mutations in exons 12, 14, and 18, including the exon 18 D842V mutation, involved in a subset of GIST3,4.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia5, Canada6, China7, Hong Kong8, Switzerland1, Taiwan8, and the United States9. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations and timing regarding potential European Commission decision on marketing approval for QINLOCK in fourth-line GIST and ensuring QINLOCK access for GIST patients in the European Union. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "seek," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the severity and duration of the impact of COVID-19 on our business and operations, our ability to successfully demonstrate the efficacy and safety of our drug candidates and in additional indications for our existing drug, the preclinical or clinical results for our product candidates, which may not support further development of such product candidates, our ability to manage our reliance on sole-source third parties such as our third party drug substance and drug product contract manufacturers, comments, feedback and actions of regulatory agencies, our ability to commercialize QINLOCK and execute on our marketing plans for any drugs or indications that may be approved in the future, our ability to build and scale our operations to support growth in additional geographies, the inherent uncertainty in estimates of patient populations, competition from other products, our ability to obtain and maintain reimbursement for any approved product and the extent to which patient assistance programs are utilized, our ability to comply with healthcare regulations and laws, our ability to obtain, maintain and enforce our intellectual property rights, any or all of which may affect the initiation, timing and progress of clinical studies and the timing of and our ability to obtain additional regulatory approvals, and other risks identified in our Securities and Exchange Commission (SEC) filings, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.
Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.
References
Swiss medicinal product information.
Blay JY, Serrano C, Heinrich MC et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21:923–934.
Smith B et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 2019; 35:738–751.
Bauer S, Heinrich M, et al. Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT/PDGFRA mutations in the phase 3 INVICTUS study. Clinical Cancer Research [online] September 9, 2021. Available from: https://clincancerres.aacrjournals.org/content/early/2021/09/08/1078-0432.CCR-21-1864 [Last accessed: September 2021].
Deciphera Press Release: Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] July 14, 2020. Available from: https://investors.deciphera.com/news-releases/news-release-details/deciphera-announces-australian-therapeutic-goods-administrations [Last accessed: September 2021].
Deciphera Press Release: Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] June 22, 2020. Available from: https://investors.deciphera.com/news-releases/news-release-details/deciphera-announces-health-canadas-authorization-qinlocktm [Last accessed: September 2021].
Zai Lab Press Release: China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) [online] March 31, 2021. Available from: https://zailab.gcs-web.com/news-releases/news-release-details/china-nmpa-approves-qinlockr-ripretinib-treatment-advanced [Last accessed: September 2021].
Zai Lab Press Release: QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) [online] September 1, 2021. Available from: https://zailab.gcs-web.com/news-releases/news-release-details/qinlockr-ripretinib-approved-taiwan-treatment-advanced [Last accessed: September 2021].
Deciphera Press Release: FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] May 15, 2020. Available from: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm [Last accessed: September 2021].
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005254/en/
Contacts
Investor Relations:
Jen Robinson
Deciphera Pharmaceuticals, Inc.
[email protected]
781-906-1112
Media:
David Rosen
Argot Partners
[email protected]
212-600-1902
The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ: AXSM), and consider why this company still has some serious potential.
Moderna stock popped Thursday as a Food and Drug Administration panel of experts met to discuss the merits of its Covid booster shot.
Late last month, Pfizer (NYSE: PFE) announced that its drug, abrocitinib, was approved by Japan's Ministry of Health, Labour and Welfare (MHLW) as a treatment for patients 12 years old and up with moderate to severe atopic dermatitis or eczema. Japan's regulatory approval of abrocitinib under its trade name of Cibinqo came just weeks after approval by the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for adults and adolescents with moderate to severe eczema. Let's dig into why the MHLW approved the drug for its eczema indication, as well as its sales potential and what it means for Pfizer.
The monoclonal antibody therapy, which is marketed under the name REGEN-COV, is currently available under an emergency-use authorization.
The U.S. Food and Drug Administration (FDA) granted approval for the company's autoimmune drug, avacopan, which instantly led to shares of ChemoCentryx more than doubling in value. For investors who didn't want to take on the risk heading into the FDA decision, the obvious question now is whether it's too late to invest in the healthcare stock. After amassing such impressive returns over a short time frame, can investors who buy the stock today still expect to earn a good return on their investment?
"Anyone who exists in a fat body has a horror story about a time they were simply trying to enjoy food in public."
Misinformation and disinformation campaigns continue to hamper the U.S. efforts to vaccinate a majority of its population. Two health experts break down the multi-pronged problem.
Palo Alto Networks (NYSE: PANW), Alnylam Pharmaceuticals (NASDAQ: ALNY), and Xenon Pharmaceuticals (NASDAQ: XENE) put up big gains for their shareholders recently. Shares of Palo Alto Networks have soared around 42% in 2021. The company is still losing money on a GAAP basis, but Palo Alto reported adjusted earnings that reached $162 million during the fiscal fourth quarter ended July 31, 2021.
Analysts were split Wednesday as they compared Crispr's gene-edited cancer drug to Allogene's — but CRSP stock tumbled as ALLO stock popped.
The advent of Covid-19 also bought with it the rise of the coronavirus stocks. The phenomenon saw shares of previously unknown companies attain improbable heights in 2020, based on the potential to bring to market solutions to blunt the pandemic’s impact. For a while, hardly soared any higher than Vaxart (VXRT). The small vaccine maker boasts one big USP – its potential Covid-19 vaccine is in pill form, a godsend for the needle-shy. But Vaxart has fallen way behind in its vaccine’s development a
Is AbbVie stock a buy as shares make a comeback on promising news for its drugs, Skyrizi and Rinvoq, in inflammatory conditions?
People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc /BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday. The study, which is preliminary and hasn't been peer reviewed, is the latest challenge to J&J's efforts to use its COVID-19 vaccine as a booster in the United States. The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson & Johnson, showed that "mixing and matching" booster shots of different types is safe in adults.
Take action instead of just crossing off the days until you turn 65.
Cancer treatment company Novocure (NASDAQ: NVCR), which uses low-power electrical fields to disrupt the growth of cancer cells, is now trading 50% below its highs. The company has numerous clinical trials of its technology underway, but traders sold the stock lower after its most recent quarterly earnings report came and went without fresh approvals for new indications from the U.S. Food and Drug Administration (FDA). Let's start by addressing the elephant in the room — the company's need of new regulatory approvals for its tech to be used in treating additional types of cancers.
(Bloomberg) — Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.Most Read from BloombergHow France Turned the Humble Roundabout Into a Showcase for ArtWhat the Front Line of the U.S. Abortion Fight in Kentucky Looks Like NowWhat Comes After GE’s 129 Years of Greenhouse GasThey Invented the Must-Have Instrument for the
Shares of Regeneron Pharmaceuticals Inc. gained 2.7% in premarket trading on Thursday after the company said the Food and Drug Administration accepted its application for approval of its monoclonal antibody treatment for non-hospitalized COVID-19 patients and as a prophylaxis for some people who have been exposed to the virus. The FDA said it will decide whether to approve the therapy by April 13 based on the priority review designation it granted to the application. It plans to hold an advisory
Before the pandemic, most of us probably didn't spend a lot of time thinking about messenger RNA (mRNA). The biotech company brought mRNA to center stage when it began developing its coronavirus vaccine. The vaccine uses mRNA to instruct the body's cells to produce a specific protein.
TUSKEGEE, Ala. — By the time vaccines for the coronavirus were introduced late last year, the pandemic had taken two of Lucenia Williams Dunn’s close friends. Still, Dunn, a former mayor of Tuskegee, contemplated for months whether to be inoculated. It was a complicated consideration, framed by the government’s botched response to the pandemic, its disproportionate toll on Black communities and an infamous 40-year government experiment for which her hometown is often associated. “I thought about
"People with body dysmorphia do not really see themselves as the world sees them," one expert tells Yahoo Life.
Coronavirus cases are declining, finally, but the debate over the vaccine is not abating. During the White House COVID press briefing today, an NPR reporter asked about some airline pilots having reservations about getting the COVID vaccine because there may be "long-term side effects" from the vaccine "that could cause them to then lose their medical certification." In response, Dr. Anthony Fauci, the chief medical advisor to the President and the director of the National Institute of Allergy a

source